Curasight
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Internationally (various countries)
About Us
Curasight is built on more than a decade of research in Positron Emissions Tomography (PET) imaging in cancer at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
A scientific team led by Professor Andreas Kjaer, developed over the last 8 years the concept of PET imaging of urokinase-type plasminogen activator receptor (uPAR), a known marker of cancer aggressiveness, to be used for improved diagnosis, risk stratification and treatment planning/monitoring in multiple types of cancer.
From a large number of uPAR-PET tracers that were tested by the team in preclinical models, a lead candidate was chosen. In close partnership between Curasight and Rigshospitalet this most promising ligand has been further developed into uTRACE®, the key product of Curasight.